Dr. Buchwald is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Johns Hopkins Gastroenterology Green Spring Station
2360 W Joppa Rd
Lutherville, MD 21093Phone+1 410-933-7495
Education & Training
- London School of Hygiene and Tropical MedicineMS, Public Health, 2014 - 2019
- NYU Grossman School of MedicineFellowship, Infectious Disease, 2007 - 2010
- NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
- Freie University Berlin Faculty of MedicineClass of 1998
Certifications & Licensure
- MD State Medical License 2010 - 2026
- PA State Medical License 2016 - 2018
- NJ State Medical License 2010 - 2011
- NY State Medical License 2009 - 2011
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- 19 citationsImmunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.Myron J. Levin, Ulrike K. Buchwald, Julie L. Gardner, Jason C. Martin, Jon E. Stek
Vaccine. 2018-01-02 - 29 citationsEfficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evid...Michael S. Niederman, Temitope Folaranmi, Ulrike K. Buchwald, Luwy Musey, Allan W. Cripps
Expert Review of Vaccines. 2021-02-20 - 3 citationsPneumococcal Vaccine Breakthrough and Failure in Infants and Children: A Narrative Review.Kristen Feemster, Jessica Weaver, Ulrike Buchwald, Natalie Banniettis, Kara S Cox
Vaccines. 2023-11-24
Press Mentions
- Pancreatic Cancer Clinical Trials: Insights from PanCAn’s Senior DirectorDecember 16th, 2023
- CMV Vaccine Trials: Moderna’s CMV mRNA Vaccine Enters Phase IIIFebruary 20th, 2024
- Merck’s Capvaxive Wins FDA Approval as First Pneumonia Vaccine Designed for AdultsJune 22nd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: